

#### **Call for Proposals**

# EUROPEAN REFERENCE LABORATORY NETWORK FOR TUBERCULOSIS (ERLTB-Net) - TO STRENGTHEN TB DIAGNOSIS IN THE EUROPEAN UNION AND EUROPEAN ECONOMIC AREA

Reference: Grant/2017/OCS/8624

Deadline for submission of proposals: 5th February 2018

#### CALL FOR PROPOSALS - Grant/2017/OCS/8624

#### EUROPEAN REFERENCE LABORATORY NETWORK FOR TUBERCULOSIS (ERLTB-Net) - TO STRENGTHEN TB DIAGNOSIS IN THE EUROPEAN UNION AND EUROPEAN ECONOMIC AREA

#### **Table of Contents**

1.	BACKGROUND1		
	1.1.	Tuberculosis (TB)	1
	1.2.	European Centre for Disease Prevention and Control (ECDC)	1
	1.3.	European Reference Laboratory Network for Tuberculosis	1
	1.4.	Molecular typing for surveillance of TB	2
	1.5.	Synergy with Pan-European and global TB initiatives	2
2.	OBJECTIVES, ACTORS AND ACTIVITIES3		
	2.1.	Objectives of the action	3
	2.2.	Main actors	3
	2.3.	Actions and the action results of the Framework Partnership Agreemen 4	1t
	2.4.	Meetings1	4
3.	TIM	ETABLE1	5
4.	BUDGET AVAILABLE16		
5.	ADMISSIBILITY REQUIREMENTS1		6
6.	ELIC	GIBILITY CRITERIA1	6
	6.1.	Eligible applicants	6
	6.2.	Eligible activities	7
7.	IMPI	LEMENTATION PERIOD1	7
8.	EXC	LUSION CRITERIA1	8
	8.1.	Exclusion1	8
	8.2.	Remedial measures1	9
	8.3.	Rejection from the call for proposals1	9
	8.4.	Supporting documents	0
9.	SELECTION CRITERIA20		
	9.1.	Financial capacity2	0
	9.2.	Operational capacity	1
10.	AWA	ARD CRITERIA2	2
11.	LEGAL COMMITMENTS		3
12.	FINANCIAL PROVISIONS		3

	12.1. Eligible costs	23
	12.1.1. Eligible direct costs	23
	12.1.2. Eligible indirect costs (overheads)	23
	12.2. Ineligible costs	23
	12.3. Form of the grant	23
	12.3.1. Reimbursement of costs actually incurred	23
	12.4. Balanced budget	24
	12.5. Calculation of the final grant amount	24
	12.6. Reporting and payment arrangements	24
	12.7. Other financial conditions	25
13.	PUBLICITY	26
	13.1. By the Partner	26
	13.2. By ECDC	26
14.	PROCESSING OF PERSONAL DATA	27
15.	PROCEDURE FOR THE SUBMISSION OF PROPOSALS	27

#### 1. BACKGROUND

#### **1.1.** Tuberculosis (TB)

TB remains an important threat to human health worldwide. In the EU/EEA, the TB situation has improved over the past decades, but TB needs to remain on the agenda due to:

- An increasing global problem with multidrug-resistant TB (MDR TB) and extensively drug-resistant TB (XDR TB) that also affects Europe;
- The disproportionately high burden of disease in vulnerable populations;
- Medium to high TB incidence in some EU Member States and a number of neighbouring countries.

#### **1.2.** European Centre for Disease Prevention and Control (ECDC)

The ECDC Founding Regulation<sup>1</sup> states that ECDC, within its mandate, shall coordinate the surveillance activities at the Community level as well as other activities important for identification, assessment, and communication of emerging threats to human health from communicable diseases.

ECDC does not have any laboratories of its own and relies on Member States' laboratory expertise and capacity. According to its Founding Regulation, it is ECDC's role:

- To support networking activities of the competent bodies recognised by the Member States;
- To encourage cooperation between expert and reference laboratories;
- To foster development of sufficient capacity within the Community for diagnosis, detection, identification, and characterisation of infectious agents which may threaten public health;
- To maintain and extend cooperation and support for the implementation of quality assessment schemes.

The ECDC TB programme plans, implements, monitors and evaluates all aspects of TB prevention and control in the EU. This includes TB surveillance in the WHO European Region which ECDC and the WHO Regional Office for Europe have jointly coordinated since 2008.

#### 1.3. European Reference Laboratory Network for Tuberculosis

In 2008, a situation analysis of national TB reference functions across the EU and EEA was conducted and led to the creation of the European Reference Laboratory Network for Tuberculosis (ERLN-TB). In 2014, ECDC commissioned a renewal of the network (now called ERLTB-Net) involving the centres from the same Member States and new institutions from EU Enlargement Countries joining in.

<sup>&</sup>lt;sup>1</sup> Founding Regulation (EC) No 851 /2004 of the European Parliament and of the Council of 21 April 2004 establishing a European Centre for disease prevention and control (http://eur-lex.europa.eu/LexUriSery/LexUriServ.do?uri=CELEX:32004R0851:EN:HTML)

The key roles of national reference laboratory services identified by Drobniewski et al.<sup>2</sup> remain valid:

- (1) identify mycobacterial cultures as *Mycobacterium tuberculosis* or non-tuberculous mycobacteria;
- (2) analyse first- and second-line drug resistance of TB cultures;
- (3) perform rapid identification and detection of at least rifampicin (RIF) resistance in patient specimens;
- (4) develop protocols and standard operation procedures;
- (5) set standards and run external quality assessment schemes (with partners);
- (6) be involved in operational research such as the validation of new diagnostics;
- (7) provide clinical and relevant public health advice on the treatment of TB;
- (8) advise on laboratory issues relating to national TB programmes; and
- (9) perform molecular typing of *M. tuberculosis* strains to support public health actions in geographically or time-defined settings and to answer specific questions on transmission.

#### 1.4. Molecular typing for surveillance of TB

Since 2015, molecular typing data of MDR TB have been included in routine EU-level surveillance with the mycobacterial interspersed repetitive units (MIRU) - variable number of tandem repeats (VNTR) 24 loci and spoligotyping methods according to the agreed standards<sup>3</sup>. Currently, 19 EU/EEA Member States have the capacity to perform molecular typing.

In recent years, whole genome sequencing (WGS) has emerged as a potentially powerful tool for the surveillance, outbreak investigation and drug resistance monitoring of human infectious pathogens including *M. tuberculosis*. Just like MIRU-VNTR, WGS can detect transmission events missed by epidemiological investigation and can discriminate relapsed TB from re-infection. In addition, WGS also offers superior resolution of genomic information compared to conventional methods<sup>4</sup>.

In 2015, ECDC developed an expert opinion on WGS in consultation with multidisciplinary experts. The resulting strategy envisages that within five years ECDC will have contributed to the establishment of standards and systems enabling EU-wide use of WGS as the method of choice for typing of microbial pathogens, replacing other methods<sup>5</sup>.

#### 1.5. Synergy with Pan-European and global TB initiatives

The Directorate General for Research and Innovation of the European Commission has funded TB projects of public health relevance (i.e. diagnosis, vaccine and drug development) for a number of years as part of the Framework Programmes (FPs) and Horizon 2020<sup>6</sup>. Further initiatives to consider are WHO's End TB Strategy<sup>7</sup>,

<sup>&</sup>lt;sup>2</sup> Drobniewski, FA, V Nikolayevskyy, S Hoffner, O Pogoryelova, D Manissero, AJ Ozin. The added value of a European Union tuberculosis reference laboratory network – analysis of the national reference laboratory activities. Euro Surveill 2008;13(12).

<sup>&</sup>lt;sup>3</sup> De Beer, J., et al., Molecular surveillance of multi- and extensively drug-resistant tuberculosis transmission in the European Union from 2003 to 2011. Euro Surveill, 2014. 19(11).

<sup>&</sup>lt;sup>4</sup> Satta, G., A. Atzeni, and T.D. McHugh, *Mycobacterium tuberculosis and whole genome sequencing: a practical guide and online tools available for the clinical microbiologist.* Clin Microbiol Infect, 2016.

<sup>&</sup>lt;sup>5</sup> European Centre for Disease Prevention and Control. Expert opinion on whole genome sequencing for public health surveillance. Stockholm: ECDC; 2016. <a href="http://ecdc.europa.eu/en/publications/Publications/whole-genome-sequencing-for-public-health-surveillance.pdf">http://ecdc.europa.eu/en/publications/Publications/Whole-genome-sequencing-for-public-health-surveillance.pdf</a>

<sup>&</sup>lt;sup>6</sup> Please refer to past projects and programmes funded by the Commission via the web portal <a href="http://cordis.europa.eu/search/index.cfm">http://cordis.europa.eu/search/index.cfm</a> <a href="http://cordis.eu/search/index.cfm">http://cordis.eu/search/index.cfm</a> <a href="http://cordis.eu/search/index.cfm">http://cordis.eu/search/index.cfm</a> <a href="http://cordis.eu/search/index.cfm">http://cordis.eu/

the European Tuberculosis Laboratory Initiative<sup>8</sup> (ELI) and the STOP TB partnership<sup>9</sup>.

#### 2. OBJECTIVES, ACTORS AND ACTIVITIES

#### 2.1. Objectives of the action

- Ensure full re-establishment and coordination of ERLTB-Net.
- In particular, enhance the further development of ERLTB-Net and exploit synergies with other supranational/global initiatives with the capacity to serve and support EU/EEA Member States and the EU Enlargement Countries, with a specific focus on TB control and elimination in the EU/EEA.
- Continue to support the EU/EEA Member States in providing reliable and timely diagnostic services.
- Support the EU/EEA Member States in implementing new laboratory techniques meeting current and future needs.
- Support the Member States and the ECDC in molecular- and genomic-based typing activities responding to public health needs in the field of TB.

#### 2.2. Main actors

**Partner:** party with whom the Framework Partnership Agreement (FPA) will be signed (see the model FPA, Annex III (a)).

**Lead partner:** the leader of a consortium, if applicable.

**Project leader:** a person employed by the partner (or by the lead partner, if a consortium), who will act as the lead for the coordination of ERLTB-Net and is the designated contact person for liaising with ECDC and ERLTB-Net.

**Project manager:** a person employed by the partner (or by the lead partner, if a consortium), who will have the overall responsibility for day-to-day project coordination and management.

**ERLTB-Net**: a network of laboratories/laboratory experts from EU/EEA Member States nominated by their National Competent Body<sup>10</sup>. The nomination process of the ERLTB-Net members is coordinated by ECDC.

**ERLTB-Net project management team:** consists of 3-5 people in addition to the project leader and project manager. If the partner is a consortium, selected representatives of consortium members should be included. The project management team selects a chairperson to run the meetings and is expected to meet regularly throughout the project duration and not less than once every 6 months. The project management team contributes technically and strategically to the project leader's work and liaises with existing initiatives funded by ECDC, the

<sup>8</sup> http://www.euro.who.int/en/health-topics/communicable-diseases/tuberculosis/activities/european-tuberculosis-laboratory-initiative
9 http://www.stoptb.org/

<sup>10</sup> Coordinating Competent Bodies: structures, interactions and terms of reference https://ecdc.europa.eu/sites/portal/files/media/en/aboutus/governance/competentbodies/Documents/coordinating-competent-bodies-structures-terms-of-reference-and-interactions-w-Annexes.pdf

European Commission and WHO. The ECDC contact person(s) attend the project management team meetings and participate fully in discussions and decision making.

**Steering committee**: may be established to oversee project activities and to ensure the quality, relevance and European added value of the project. The steering committee is appointed by ECDC, in consultation with the partner. The steering committee includes the partner (or the lead partner, if a consortium), ECDC contact person(s) and 2-3 TB/public health experts appointed by ECDC.

## 2.3. Actions and the action results of the Framework Partnership Agreement

The partner is requested to coordinate the work in agreement with and under supervision of ECDC.

ECDC expects assistance from the partner to be able to use the outputs of the network, even if such outputs are not technically results.

#### **Definitions and acronyms:**

 $\mathbf{A}$  = main action;  $\mathbf{R}$  = action result;  $\mathbf{m}$  = month (used to describe timing within the expected total duration of 48 months) of this FPA.

Dates in brackets are the preferred dates.

Data management and data exchange with ECDC are arranged according to the data protection rules (See Article 11.6.2 Processing of personal data by the partner of the Framework Partnership Agreement, Annex III(a)).

# AI. THE EUROPEAN REFERENCE LABORATORY NETWORK FOR TUBERCULOSIS (ERLTB-Net) IS FULLY ESTABLISHED AND ITS COORDINATION IS ENSURED

The tasks of A1 consist of setting up and ensuring continued coordination of the ERLTB-Net.

#### Al.1 Coordination

As per the definition of the roles of the actors in this project (see section 2.2), the partner (or the lead partner if a consortium), will act as the coordinator of the ERLTB-Net. The requested results are:

- R1.1.1 The ERLTB-Net with agreed members is set up by nomination of the ERLTB-Net members (m 1-3). The ERLTB-Net members will be nominated by the National Competent Bodies.
- R1.1.2 Monthly teleconferences with ECDC including providing minutes of the teleconferences (within one week after the teleconference).
- R1.1.3 Annual report\* on project implementation, comprising all the results of activities performed under the respective specific grant agreement (SGA).
- R1.1.4 Final report\* on the entire project period.

\* The report will include at least the following chapters: table of contents, list of abbreviations, executive summary, introduction/background, detailed description of activities, results of activities, discussion on results/lessons learned, and conclusions/next steps. The report should be written using British English grammar and spelling. The report should be consistently formatted throughout the document.

#### A1.2 ERLTB-Net project management team

As stipulated in section 2.2, the partner will propose a group of representatives from the ERLTB-Net and/or selected representatives of the partner (maximum 5 in total), who will contribute technically and strategically to the project and liaise with ECDC and existing initiatives of ECDC, the European Commission and WHO. The terms of reference for the project management team will be developed jointly with ECDC.

It is expected that a maximum of 3 face-to-face meetings (1-2 day meetings) will be necessary each year. Teleconferencing will be used in between the face-to-face meetings. One meeting will be organised back-to-back with the annual network meeting and one at ECDC premises in Stockholm, Sweden. Travel, accommodation and relevant subsistence expenses for the project management team members (excluding ECDC employees) and for any additionally invited external expert(s) will be covered by the partner. The organisation of the meetings should follow the general rules described in section 2.4.

The requested results are:

- R1.2.1 ERLTB-Net project management team with agreed members is set up (m 1-3).
- R1.2.2 The terms of reference for the ERLTB-Net project management team is approved by ECDC (m 1-3).
- R1.2.3 The project management team meetings and teleconferences are organised and the minutes\* of the meetings / teleconferences are provided to ECDC (within two weeks after the face-to-face meeting, and within one week after the teleconference).

#### A1.3 Annual meeting and large capacity building workshop

The partner, (or the lead partner if a consortium), will organise one meeting and large capacity building workshop for the ERLTB-Net members every year in one of the EU/EEA Member States. The organisation of these meetings should follow the general rules described in section 2.4. In addition:

• The meeting and large capacity building workshop will be attended by the ERLTB-Net members and include nominated persons from all Member

<sup>\*</sup> The minutes should include at least the following: title of the meeting, date and time, venue, list of attendees, list of apologies, list of abbreviations, detailed description of discussion, summary of decisions with agreed deadlines and personal responsibilities. The minutes should be written using British English grammar and spelling. The minutes should be consistently formatted throughout the document.

States, plus any additional participant(s) requested by ECDC. The EU enlargement countries are welcome to the meeting as observers either funded by other EU projects or on their own funding. Other country participants and invited colleagues from relevant organisations (e.g. WHO, European Commission) may attend as observers, but on their own funding.

- By default, one ERLTB-Net member per EU/EEA Member State should be invited. If the budget of the SGA allows, an additional ERLTB-Net member (e.g. molecular typing contact) can be invited from the Member State.
- The maximum number of participants, including invited speakers, should not exceed 50 persons, excluding representatives from EU enlargement countries, ECDC employees and invited colleagues from relevant organisations.
- The agenda and the main topics for the meeting and the agenda for the large capacity building workshop will be agreed with and approved by ECDC.
- The format of the meeting and the large capacity building workshop will be agreed in advance with ECDC.

#### The requested results are:

- R1.3.1 The annual meeting and large capacity building workshop are organised and implemented.
- R1.3.2 A detailed report<sup>#</sup> on the annual meeting and the large capacity building workshop is provided (within one month after the event).

<sup>&</sup>lt;sup>#</sup> The report should include at least the following chapters: table of contents, list of abbreviations, executive summary, introduction/background, detailed description of activities, results of activities, discussion on results/lessons learned, and conclusions/next steps. The report should be written using British English grammar and spelling. The report should be consistently formatted throughout the document.

# A2. EXTERNAL QUALITY ASSESSMENT (EQA) SCHEMES FOR TB LABORATORY METHODS ARE DESIGNED AND SCHEMES FOR NEW METHODS ARE ESTABLISHED

The partner will, in accordance with ECDC EQA strategy (to be provided by ECDC), maintain and further develop the existing EQA schemes for TB laboratory diagnostic methods routinely used by the laboratories in the EU/EEA. Every year one EQA round for the ERLTB-Net members will be organised. Inclusion of the EU enlargement countries into EQA activities might be requested by ECDC depending on the budget availability. During the EQA implementation, related ongoing activities/projects funded by the European Commission should be identified and taken into account. It should be assessed how the ERLTB-Net EQA activities interact with global initiatives supported by the WHO to build synergies and avoid duplication of efforts.

The partner is not expected to be a specialist in all techniques covered by the EQA schemes proposed. Arrangements with appropriate specialists among ERLTB-Net members - or other institutes or private companies - can be used to fulfil part or all of the EQA tasks (A2). In general:

- The partner will prepare an approach on how to provide EQA schemes to national reference laboratories and promote their participation. The EQA schemes are to cover diagnostic methods routinely used by the laboratories in the EU/EEA (e.g. culture, microscopy, molecular assays), first and second-line drug susceptibility testing (e.g. phenotypic, molecular assays, WGS) and molecular typing methods (e.g. WGS, MIRU-VNTR) to ensure that laboratories of the ERLTB-Net members and beyond produce valid and comparable data.
- Develop EQA schemes for new diagnostic methods and genotyping techniques.
- The partner will work with the ECDC contact person(s) at all steps during implementation of EQA.
- The ERLTB-Net management team will guide the development of EQA methods, protocols, services, and follow-up training.

#### **A2.1** Establishment of the current performance

Using experiences from existing TB EQA initiatives, the partner will design a proficiency round in agreed areas of TB diagnostic services (e.g. microscopy, culture, drug susceptibility testing) including molecular typing (e.g. WGS) to confirm or establish a new baseline of performance for ERLTB-Net members and to help identify future needs for collaboration and training within the network (refer to A3 of training and use of task forces to improve proficiency testing performance).

The requested results are:

R2.1.1 Summary report on EQA performance for all methods included in the ERLTB-Net EQA. For methods that were also in the past EQA exercises

a comparison with results in previous years should be made. This summary report establishes the baseline EQA performance.

#### **A2.2** Development of future EQA schemes

The partner will identify the areas where an EQA scheme exists or should be developed in the area of TB diagnostic services (e.g. microscopy, culture, drug susceptibility testing) and molecular typing (e.g. WGS), following the recommendations in international guidelines and existing standards.

The requested results are:

- R2.2.1 Description of the existing EQA system in diagnostic and molecular typing techniques and additional techniques to be included into the EQA.
- R2.2.2 Developed EQA work plan on implementation of regular EQA rounds.
- R2.2.3 Developed proficiency testing scheme for new methods (based on R2.1.1) that helps to establish a performance baseline for ERLTB-Net members.
- R2.2.4 Report on training needs to support improvements in performance in order to meet EQA standards (refer to A3 on training for improving EQA performance).

#### A2.3 Implementation of regular EQA rounds and data analysis

Following the EQA work plan (see R2.2.3), the partner will perform annual EQA rounds, collection and analysis of EQA results. The non-anonymised EQA results by country will be shared with ECDC for internal use only. The non-anonymised EQA results by country will not be published by ECDC, but used to ensure tailored technical support to laboratories with suboptimal performance for specific tests.

The requested results are:

- R2.3.1 EQA system described in R2.2.1 is implemented as part of EQA rounds.
- R2.3.2 The laboratory certification (after every EQA round) based on the EQA results.
- R2.3.3 An annual summary EQA report\* with anonymised data is produced.
- \* The report should preferably follow the ECDC content template for EQA reports<sup>11</sup> and include at least the following chapters: credits, table of contents, list of abbreviations, executive summary, introduction/background, detailed description of methodology/study design, results, discussion on results including lessons learned, conclusions/next steps including the training areas identified, references and annexes. The report should provide results separately for EU/EEA, non EU/EEA countries, and all countries. The report should be written using

8

<sup>&</sup>lt;sup>11</sup> ECDC internal document. Relevant section will be provided to the partner.

British English grammar and spelling. The report should be consistently formatted throughout the document. ECDC will provide a template for the report in advance.

#### A3. TRAINING IS PREPARED AND IMPLEMENTED

Based on the identified needs, the partner will develop a training programme including large and small capacity building workshops, staff exchange visits and targeted country support with the overall aim to strengthen Member State capacity in laboratory diagnosis of TB (i.e. isolation and characterisation of *Mycobacteria*), in supporting public health activities (e.g. molecular typing) and in coordination of national TB laboratory networks.

### A3.1 Identification of training needs and development of training curricula

Under each SGA the partner will identify training needs in addition to those identified in R2.2.4 and develop the appropriate curricula for laboratory capacity building workshops, staff exchange visits and targeted country support to:

- strengthen performance in traditional diagnostic methods, DST, molecular typing, and other specialised analytical techniques for TB as well as other more general topics such as biosafety, laboratory management and quality control in the context of working with TB;
- improve EQA performance; and
- support the establishment and coordination of national TB laboratory networks.

The requested results are:

- R3.1.1 Report\* on identified training needs in laboratory methods, including molecular typing methods, diagnostics, organisation / coordination of the national TB laboratory network and other areas of TB laboratory reference services in EU/EEA Member States.
- R3.1.2 Detailed training curricula on the topics identified in R3.1.1.
- \* The report should include at least the following chapters: table of contents, list of abbreviations, executive summary, introduction/background, detailed description of methodology, results, discussion on results. The report should be written using British English grammar and spelling. The report should be consistent formatted throughout the document.

#### **A3.2** Implementation of training activities

Preferred types of training, but not exhaustive:

- Small and large capacity building workshops: their goal is to disseminate methods, identify challenges and provide solutions for overcoming them. The training has to be provided by a training organiser delegated by the partner or by the partner themselves. The topics, agenda, invitation list, location and the trainers will be agreed with ECDC.
- TB laboratory staff exchange visits or targeted country support: short visits to improve on specific methods based on the results of the EQA, provide training in specific methods to improve characterisation of

pathogens and/or specialised reference techniques, to enhance coordination of national TB laboratory networks, and to promote collaboration between ERLTB-Net members.

The training activities will be coordinated by the partner and implemented by the partner or a third party specialised in the specific area.

For cost estimation of training initiatives, please use the following scenarios as a guide:

- One large (max. 50 participants) and/or a maximum of 3 smaller laboratory training workshops (10-15 participants to cover topic-specific needs) may be requested by ECDC per 12 months. The partner will cover the travel, accommodation and relevant subsistence expenses within EU/EEA for all the participants in the workshop (maximum 3 days per workshop). The partner will also cover their own expenses and expenses of trainers/experts which will be included in the budget proposal together with the costs of participants. Travel, accommodation and subsistence expenses of ECDC staff will be covered by ECDC.
- A maximum of 3 "country support" visits should be included per 12 months (with a maximum of 2 persons visiting), unless otherwise justified by the results of A2. The partner will cover the travel, accommodation and relevant subsistence expenses for all the experts involved. The partner will also cover their own expenses which will be included in the budget estimation together with the costs of participants.
- A maximum of 2 staff exchanges per 12 months should be budgeted for. Each such staff exchange would have to be justified and approved by ECDC. The partner will cover the travel, accommodation and relevant subsistence expenses for the participants for up to one week. The partner will cover their own expenses which will be included in the budget estimation together with the costs of participants.

The requested results are:

- R3.2.1 Detailed implementation plan<sup>#</sup> of training curricula described in R3.1.2.
- R3.2.2 Training materials and training initiatives are developed and implemented during annual meetings, laboratory capacity building workshops, and in laboratory exchanges and country support visits and made available through the ECDC extranet.
- R3.2.3 Individual reports\* on each implemented training activity.
- <sup>#</sup> The implementation plan should include at least the following chapters: table of contents, list of abbreviations, executive summary, introduction/background, detailed description of implementation steps, risks and mitigation. The report should be written using British English grammar and spelling. The implementation plan should be consistently formatted throughout the document.

<sup>\*</sup> The report should include at least the following chapters: table of contents, list of abbreviations, executive summary, introduction/background, detailed description of activities, results of activities, discussion on results/lessons learned, and

conclusions/next steps. The report should be written using British English grammar and spelling. The report should be consistently formatted throughout the document.

#### A4. Reference and support activities

#### A4.1 Methods harmonisation

- The partner will propose an implementation plan for harmonisation of new TB laboratory methods in needed areas, taking into account ongoing projects at the EU/EEA and global level.
- Maintain the European "handbook" <sup>12</sup> (technical guidance) of harmonised methods as the ultimate output of the network to be used as a shared tool amongst the network members and all interested TB laboratories in the EU/EEA. The "handbook" will be made available on the ECDC public web portal.

The requested results are:

- R4.1.1 The "handbook" of TB diagnostic methods is maintained.
- R4.1.2 Developments in laboratory methodologies and techniques are followed up and new developments are to be reported to the network members and ECDC at the annual meetings and through the ECDC Extranet.
- R4.1.3 A work plan for the introduction of new methodologies and techniques into routine TB diagnosis for the National TB Reference Laboratories.

#### A4.2 Reference services

Provide a reference service catalogue and promote access to these laboratory services to network members.

The requested results are:

- R4.2.1 The list of reference services provided by the network members and the costs per service are maintained and made available to the network members in a "bio-book" format. The exact format will be agreed with ECDC.
- R4.2.2 Feedback on acting collaborations and on the use of these reference services should be provided for periods between 6 to 12 months.

#### A4.3 Alert and response

Involve the ERLTB-Net experts in contributing to the ECDC's alert and response activities.

https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/tuberculosis-laboratory-diagnostic-methods-eu.pdf

Involve at least 3 ERLTB-Net experts in the molecular typing and WGS-based typing data analysis, review and assessment of public health importance of identified clusters.

The requested results are:

R4.3.1 Upon ECDC request, ERLTB-Net supports ECDC's alert and response activities, including public health actions triggered by cluster notifications coming from ECDC's TB molecular surveillance system (estimated number of requests is 2 per year).

#### A4.4 Scientific support and excellence

ERLTB-Net experts produce at least one peer-reviewed article per year based on network activities. The network members will be encouraged to explore scientific collaborations with ECDC. The partner, or the lead partner if a consortium, will appoint a qualified ERLTB-Net member to produce the article. Co-authorship will be offered to network members and relevant ECDC staff meeting the authorship requirements described by the International Committee of Medical Journal Editors<sup>13</sup>. The partner will participate in relevant ECDC scientific activities and will promote these on relevant national and international meetings and conferences.

The requested results are:

- R4.4.1 The partner participates in and promotes ECDC's scientific activities to TB colleagues/community of experts (e.g. meetings, conferences).
- R4.4.2 At least one peer-reviewed article per year is produced based on ERLTB-Net activities.

#### A4.5 Support to national laboratory networks for tuberculosis

The partner will provide technical support to ERLTB-Net member laboratories in building, managing and assessment of national TB laboratory networks. The partner will develop a tool for self-assessment of national TB laboratory networks. Member laboratories will be encouraged to use the tool and to share the results with the partner. The partner will use the results of the self-assessment for prioritising countries for support applying a predefined algorithm for prioritization. When requested in the SGA, the partner will explore the interest of the ERLTB-Net members for receiving the support, and provide the support.

The requested results are:

- R4.5.1 Tool for the self-assessment of national TB laboratory networks.
- R4.5.2 Performed self-assessments of national TB laboratory networks.

<sup>&</sup>lt;sup>13</sup> http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html

- R4.5.3 Report\* on the performed self-assessments of national TB laboratory networks, including proposed priority list based on self-assessment results.
- R4.5.4 Action plan for targeted country support in selected countries according to the identified needs in R4.5.3.
- R4.5.5 Implemented action plan for targeted country support in selected countries according to the R4.5.4.
- R4.5.6 Report\* on the implemented targeted country support activities in selected countries.

#### 2.4. Meetings

For all meetings (including laboratory capacity building workshops), the following tasks will be carried out by the partner, (or the lead partner if in consortium):

- Propose the list of participants, provide the scope and purpose of the meeting and seek ECDC input and approval prior to sending invitations to the identified meeting participants. The scope and purpose document should describe the background, objectives, expected outcomes, and working methods of the meeting.
- Organise travel and accommodation for all participants (excl. self-funded participants), including the invited speakers. Travel and accommodation for ECDC staff will be organised by ECDC according to its internal procedures. Self-funded participants should organise their travel and accommodation themselves.
- Ensure that all participants sign the attendance list for each day of the meeting.
- The partner will cover their costs and the costs of the participants (excl. self-funded participants) including the invited speakers at the country-specific fixed rate as indicated in 11.19 Eligible Costs of the Model FPA, Annex III(a). Participant costs will be reimbursed after conclusion of the meeting/workshop and upon proof of participation by an attendance list signed by the participant for each meeting day.
- Provide an appropriate meeting venue, ensuring ideal working conditions, including all relevant equipment, such as overhead projector / video projector with connection to MS PowerPoint software, beamer, screens (if needed), flip charts (with paper and pens), easy access to printer, photocopier (with sorter and stapler function).

The report should include at least the following chapters: table of contents, list of abbreviations, executive summary, introduction/background, detailed description of activities, results of activities, discussion on results and conclusions/next steps. The report should be written using British English grammar and spelling. The report should be consistently formatted throughout the document.

- Plenary room will be 1 large room for lectures accommodating all the participants. Participants will have own laptops and will need access to outlets. There will be a dedicated presentation computer/laptop hooked up to the projector. Each participant will have enough table space for the laptop, paper notes and small (0.5 litre) bottle of refreshment (e.g. mineral water).
- Breakout room (optional) will be a smaller discussion room for group work accommodating half of the participants. Presentation screen, projector, and flipchart with pens are needed in each room.
- Free of charge Wi-Fi internet access will be provided to each participant in the meeting spaces (e.g. plenary room, breakout rooms).
- Provide catering during 2 coffee breaks per day and water on the table during meeting sessions.
- The working language at the meetings is English.
- Provide to the participants the printed and/or electronic version of background and working documentation related to the meeting in English language at least 2 weeks before the meeting.
- Ensure the necessary administrative support (including continuous on-site support) in order to allow smooth organisation and implementation of the meeting.
- Seek speakers' agreement for sharing their meeting presentations with the meeting participants and including them in the meeting report.
- Provide a detailed meeting report\*.

\*The report should include at least the following chapters: table of contents, list of abbreviations, executive summary, introduction/background, detailed description of activities, results of activities, discussion on results/lessons learned, and conclusions/next steps. As part of the meeting report, a final list of participants (including their affiliation and contact details), will be provided to ECDC in electronic (e.g. xlsx, pdf) format. The report should be written using British English grammar and spelling. The report should be consistently formatted throughout the document.

#### 3. TIMETABLE

	Stages	Date and time or indicative period
a)	Publication of the call	15/12/2017
b)	Deadline for submitting applications	<b>05/02/2018</b> – 16:00 CET
c)	Evaluation period	20/02/2018 - 06/03/2018
d)	Information to applicants	16/03/2018

e) Signature of grant agreement 11/04/2018
--

#### 4. BUDGET AVAILABLE

The total budget earmarked for the co-financing of projects is estimated at 800,000 EUR for a maximum duration of the framework partnership agreement of four years.

This amount is subject to the availability of the appropriations provided for in the draft budget for the specific year after the adoption of the budget for the respective year by the budgetary authority.

The maximum grant will be 90% of the total eligible costs, and the partner will co-finance the remaining (minimum 10%) of the total eligible costs. Such distribution will apply to every specific grant agreement within the framework partnership.

The ECDC expects to fund one proposal.

The ECDC reserves the right not to distribute all the funds available.

#### 5. ADMISSIBILITY REQUIREMENTS

- Applications must be sent no later than the deadline for submitting applications referred to in section 3.
- Applications must be submitted in writing (see section 15), using the application form available at <a href="https://ecdc.europa.eu/en/about-us/procurement-and-grants?f[0]=deadline\_date%3A1">https://ecdc.europa.eu/en/about-us/procurement-and-grants?f[0]=deadline\_date%3A1</a>
- Applications must be drafted in one of the EU official languages. ECDC prefers to receive documentation in English. Nonetheless, the choice of language will not play any role in the consideration of the application.

Failure to comply with those requirements will lead to the rejection of the application.

#### 6. ELIGIBILITY CRITERIA<sup>15</sup>

#### **6.1.** Eligible applicants

- non-profit organisation (private or public);
- public authorities (national, regional, local);
- international organisations;
- universities;
- educational institutions;
- research centres.

Legal entities having a legal or capital link with applicants, which is neither limited to the action nor established for the sole purpose of its implementation, may take part in the action as consortium members, and may declare eligible costs as specified in section 11.1.

For that purpose, applicants shall identify such consortium members in the application form.

\_

<sup>&</sup>lt;sup>14</sup> Article 131 FR.

<sup>15</sup> Article 131 FR, 201 RAP

Only applications from legal entities established in the following countries are eligible:

- EU Member States;
- EEA countries: Iceland, Liechtenstein, Norway.

For the purpose of declaring eligible costs as specified under section 11.1, the entities composing the applicant shall be treated as consortium members.

In order to assess the applicants' eligibility, the following supporting documents are requested:

- private entity: extract from the official journal, copy of articles of association, extract of trade or association register, certificate of liability to VAT (if, as in certain countries, the trade register number and VAT number are identical, only one of these documents is required);
- public entity: copy of the resolution, decision or other official document establishing the public-law entity;
- natural persons: photocopy of identity card and/or passport; certificate of liability to VAT, if applicable (e.g. some self-employed persons)
- **entities without legal personality:** documents providing evidence that their representative(s) have the capacity to undertake legal obligations on their behalf.

#### **6.2.** Eligible activities

Types of activities eligible under this call for proposals.

- cooperation projects;
- conferences, seminars;
- training activities;
- awareness and dissemination actions;
- actions aiming at the creation and improvement of networks, exchanges of good practices;
- studies, analyses, mapping projects;
- research activities.

#### 7. IMPLEMENTATION PERIOD

Activities may not start before 8<sup>th</sup> April 2018 and the date of signature of the framework partnership agreement.

Activities are to be completed by the date indicated in the respective specific grant agreement.

The maximum duration of the framework partnership agreement is four years.

Applications for projects scheduled to run for a longer period than that specified in this call for proposals will not be accepted.

#### 8. EXCLUSION CRITERIA

#### 8.1. Exclusion

The authorising officer shall exclude an applicant from participating in call for proposals procedures where:

- (a) the applicant is bankrupt, subject to insolvency or winding-up procedures, where its assets are being administered by a liquidator or by a court, where it is in an arrangement with creditors, where its business activities are suspended, or where it is in any analogous situation arising from a similar procedure provided for under national laws or regulations;
- (b) it has been established by a final judgment or a final administrative decision that the applicant is in breach of its obligations relating to the payment of taxes or social security contributions in accordance with the law of the country in which it is established, with those of the country in which the authorising officer is located or those of the country of the performance of the contract;
- (c) it has been established by a final judgment or a final administrative decision that the applicant is guilty of grave professional misconduct by having violated applicable laws or regulations or ethical standards of the profession to which the applicant belongs, or by having engaged in any wrongful conduct which has an impact on its professional credibility where such conduct denotes wrongful intent or gross negligence, including, in particular, any of the following:
  - (i) fraudulently or negligently misrepresenting information required for the verification of the absence of grounds for exclusion or the fulfilment of selection criteria or in the performance of a contract, a grant agreement or a grant decision;
  - (ii) entering into agreement with other applicants with the aim of distorting competition;
  - (iii) violating intellectual property rights;
  - (iv) attempting to influence the decision-making process of the ECDC during the award procedure;
  - (v) attempting to obtain confidential information that may confer upon it undue advantages in the award procedure;
- (d) it has been established by a final judgment that the applicant is guilty of any of the following:
  - (i) fraud, within the meaning of Article 1 of the Convention on the protection of the European Communities' financial interests, drawn up by the Council Act of 26 July 1995;
  - (ii) corruption, as defined in Article 3 of the Convention on the fight against corruption involving officials of the European Communities or officials of Member States of the European Union, drawn up by the Council Act of 26 May 1997, and in Article 2(1) of Council Framework Decision 2003/568/JHA, as well as corruption as defined in the law of the country where the contracting authority is located, the country in which the applicant is established or the country of the performance of the contract;
  - (iii) participation in a criminal organisation, as defined in Article 2 of Council Framework Decision 2008/841/JHA;

- (iv) money laundering or terrorist financing, as defined in Article 1 of Directive 2005/60/EC of the European Parliament and of the Council;
- (v) terrorist-related offences or offences linked to terrorist activities, as defined in Articles 1 and 3 of Council Framework Decision 2002/475/JHA, respectively, or inciting, aiding, abetting or attempting to commit such offences, as referred to in Article 4 of that Decision;
- (vi) child labour or other forms of trafficking in human beings as defined in Article 2 of Directive 2011/36/EU of the European Parliament and of the Council;
- (e) the applicant has shown significant deficiencies in complying with main obligations in the performance of a contract, a grant agreement or a grant decision financed by the Union's budget, which has led to its early termination or to the application of liquidated damages or other contractual penalties, or which has been discovered following checks, audits or investigations by an authorising officer, OLAF or the Court of Auditors;
- (f) it has been established by a final judgment or final administrative decision that the applicant has committed an irregularity within the meaning of Article 1(2) of Council Regulation (EC, Euratom) No 2988/95.
- (g) for the situations of grave professional misconduct, fraud, corruption, other criminal offences, significant deficiencies in the performance of the contract or irregularity, the applicant is subject to:
  - (i) facts established in the context of audits or investigations carried out by the Court of Auditors, OLAF or internal audit, or any other check, audit or control performed under the responsibility of an authorising officer of an EU institution, of a European office or of an EU agency or body;
  - (ii) non-final administrative decisions which may include disciplinary measures taken by the competent supervisory body responsible for the verification of the application of standards of professional ethics;
  - (iii) decisions of the ECB, the EIB, the European Investment Fund or international organisations;
  - (iv) decisions of the Commission relating to the infringement of the Union's competition rules or of a national competent authority relating to the infringement of Union or national competition law.
  - (v) decisions of exclusion by an authorising officer of an EU institution, of a European office or of an EU agency or body.

#### 8.2. Remedial measures

If an applicant declares one of the situations of exclusion listed above (see section 8.1), it should indicate the measures it has taken to remedy the exclusion situation, thus demonstrating its reliability. This may include e.g. technical, organisational and personnel measures to prevent further occurrence, compensation of damage or payment of fines. The relevant documentary evidence which illustrates the remedial measures taken must be provided in annex to the declaration. This does not apply for situations referred in point (d) of section 8.1.

#### 8.3. Rejection from the call for proposals

The authorising officer shall not award a grant to an applicant who:

- a. is in an exclusion situation established in accordance with section  $8.1^{16}$ ;
- b. has misrepresented the information required as a condition for participating in the procedure or has failed to supply that information;
- c. was previously involved in the preparation of calls for proposal documents where this entails a distortion of competition that cannot be remedied otherwise.

The same exclusion criteria apply to consortium members.

Administrative and financial penalties may be imposed on applicants, or consortium members where applicable, who are guilty of misrepresentation.

#### 8.4. Supporting documents<sup>17</sup>

Applicants and consortium members must provide a declaration on their honour certifying that they are not in one of the situations referred to in articles 106(1) and 107 FR, by filling in the relevant form attached to the application form accompanying the call for proposals and available at <a href="https://ecdc.europa.eu/en/about-us/procurement-and-grants?ff0]=deadline\_date%3A1.">https://ecdc.europa.eu/en/about-us/procurement-and-grants?ff0]=deadline\_date%3A1.</a>

This obligation may be fulfilled in one of the following ways:

- (i) the applicant signs a declaration in its name and on behalf of the consortium members OR
- (ii) the applicant and the consortium members sign each a separate declaration in their own name.

#### 9. SELECTION CRITERIA<sup>18</sup>

An evaluation of the quality of the applications and of the capacity of the grant applicant and its partners, will be subsequently carried out in accordance with the evaluation criteria set out in the Evaluation Grid included below. There are two types of evaluation criteria: selection and award criteria.

#### 9.1. Financial capacity<sup>19</sup>

entities.

Applicants must have stable and sufficient sources of funding to maintain their activity throughout the duration of the grant and to participate in its funding. The applicants' financial capacity will be assessed on the basis of the following supporting documents to be submitted with the application:

- a declaration on their honour;
- an audit report produced by an approved external auditor certifying the accounts for the two last financial years.
   In the case of legal entities forming one applicant (the "sole applicant"), as specified in section 6.1, the above requirements apply to each one of those

<sup>17</sup> Article 197 RAP

<sup>&</sup>lt;sup>16</sup> Article 106 FR

<sup>&</sup>lt;sup>18</sup> Article 132 FR, 202 RAP

<sup>&</sup>lt;sup>19</sup> Article 131, 132 FR, 202 RAP.

and

#### **EITHER**

- ➤ the profit and loss account as well as the balance sheet for the last financial year for which the accounts were closed;
- for newly created entities: the business plan might replace the above documents:

#### OR

➤ the table provided for in the application form, filled in with the relevant statutory accounting figures, in order to calculate the ratios as detailed in the form.

On the basis of the documents submitted, if the ECDC considers that financial capacity is weak, s/he may:

- request further information;
- decide not to give pre-financing;
- decide to give pre-financing paid in instalments;
- decide to give pre-financing covered by a bank guarantee (see section 11.4 below);
- where applicable, require the joint and several financial liability of all the cobeneficiaries.

If the ECDC considered that the financial capacity is insufficient s/he will reject the application.

#### 9.2. Operational capacity<sup>20</sup>

Applicants must have the appropriate qualifications as well as the professional competencies necessary to complete the proposed actions:

- Have the management capacity, professional competencies and qualifications required to successfully complete the proposed actions. This also applies to any partner of the grant applicant;
- Proofs of relevant expertise and experience by documenting activities of the applicant in the areas of actions described in paragraphs 2.3, 2.4 and 2.5

In this respect, applicants have to submit a declaration on their honour, and the following supporting documents:

- curriculum vitae or description of the profile of the people primarily responsible for managing and implementing the action (accompanied where appropriate, like in the field of research and education, by a list of relevant peer-reviewed publications);
- the organisation's activity reports, i.e. introduction of the organisation's work areas relevant to this action in last 3 years;
- an exhaustive list of previous projects and activities performed that are connected to the actions to be carried out;

-

<sup>&</sup>lt;sup>20</sup> Article 131 FR, 202 RAP.

- a description of the technical equipment, tools or facilities and patents at the disposal of the applicant;
- an inventory of natural or economic resources involved in the project.

In the case of legal entities forming **one** applicant (the "sole" applicant), as specified in section 6.1, the above requirements apply to each one of those entities.

#### 10. AWARD CRITERIA<sup>21</sup>

<u>The award criteria</u> allow the quality of the applications submitted to be evaluated in relation to the set objectives and priorities. They enable the selection of applications which ECDC can be confident will meet its needs and preferences. The following award criteria will be used:

#### **Evaluation Grid**

Criteria	Maximum Score
Composition of the team: The degree to which the applicant demonstrates logically and soundly, that the structure and organization of the team will allow the partner to mobilize experts and assign them to the activities.	
<ul> <li>The quality of the proposal to meet the objectives as demonstrated by:</li> <li>the extent to which the proposed implementation plan and milestones credibly responds to this call for proposals;</li> <li>the extent to which the application addresses the needs of the coordination of the ERLTB-Net;</li> <li>the quality of the proposed methods for carrying out the actions and the envisaged impact of the disseminated results;</li> <li>the extent to which the application identifies the possible risks to the project implementation and the quality of proposed mitigation actions.</li> <li>The above aspects are of the same relative value.</li> </ul>	70
Maximum total score	

#### Scoring:

Only applications scoring **75 points** or more (of a maximum of 100) points will be awarded a grant.

Applications scoring less than 60% for any individual award criterion will be deemed to be of insufficient quality and eliminated from further consideration.

\_

<sup>&</sup>lt;sup>21</sup> Article 132 FR, 203 RAP

#### 11. LEGAL COMMITMENTS<sup>22</sup>

In the event the application for framework partnership is selected, a framework partnership agreement detailing the conditions of cooperation will be sent to the applicant, as well as information on the procedure to formalise the agreement of the parties. See the Model FPA, Annex III(a).

#### 12. FINANCIAL PROVISIONS

#### 12.1. Eligible costs

Eligible costs shall meet all the criteria stated in the Model FPA, Article II.191, Annex III(a).

Eligible costs may be direct or indirect.

#### 12.1.1. Eligible direct costs

The eligible direct costs are defined in Article II.19.2 of the Model FPA, Annex III(a).

#### 12.1.2. Eligible indirect costs (overheads)<sup>23</sup>

See Article II.19.3 of the Model FPA for details of the indirect costs.

A flat-rate amount of 7% of the total eligible direct costs of the action, is eligible as indirect costs, representing the partner's general administrative costs which can be regarded as chargeable to the action/project.

#### 12.2. Ineligible costs

Please refer to the Model FPA, Article II.19.4 for the list of ineligible costs.

#### 12.3. Form of the grant

#### 12.3.1. Reimbursement of costs actually incurred $\frac{24}{}$

The grant will be defined by applying a maximum co-financing rate of 90% to the eligible costs <u>actually</u> incurred and declared by the partner (see Article II.20.1 of the Model FPA, Annex III(a)).

<sup>&</sup>lt;sup>22</sup> Article 121 FR, 174 RAP.

<sup>&</sup>lt;sup>23</sup> Indirect costs do not apply to operating grants.

<sup>&</sup>lt;sup>24</sup> Article 126 FR

#### 12.4. Balanced budget<sup>25</sup>

The estimated budget of the action must be attached to the application form. It must have revenue and expenditure in balance.

The budget must be drawn up in euros.

The applicant must ensure that the resources which are necessary to carry out the action are not be entirely provided by the EU grant.

Co-financing of the action may take the form of:

- the partner's own resources,
- income generated by the action or work programme,
- financial contributions from third parties.

#### 12.5. Calculation of the final grant amount

The final amount of the grant is calculated by ECDC at the time of the payment of the balance. The calculation involves the following steps:

#### Step 1 — Application of the reimbursement rate to the eligible costs

The amount under step 1 is obtained by application of the reimbursement rate specified in section 12.3.1 to the eligible costs accepted by the ECDC, to which the co-financing rate applies in accordance with section 12.3.

#### Step 2 — Limit to the maximum amount of the grant

The total amount paid to the beneficiaries by the ECDC may in no circumstances exceed the maximum amount of the grant as indicated in the grant agreement. If the amount obtained following Step 1 is higher than this maximum amount, the final amount of the grant is limited to the latter.

## Step 3 — Reduction due to improper implementation or breach of other obligations.

ECDC may reduce the maximum amount of the grant if the action has not been implemented properly (i.e. if it has not been implemented or has been implemented poorly, partially or late), or if another obligation under the Agreement has been breached.

The amount of the reduction will be proportionate to the degree to which the action has been implemented improperly or to the seriousness of the breach.

#### 12.6. Reporting and payment arrangements 26

The partner may request payment as per the provisions of the Model SGA, Article 4 (Annex III(b)):

\_

<sup>&</sup>lt;sup>25</sup>Article 196.2 RAP

<sup>&</sup>lt;sup>26</sup> Article 90, 135 FR, 207 RAP.

Payment request	Accompanying documents
A <b>pre-financing payment</b> <sup>27</sup> corresponding to 40% of the grant amount	
One interim payment <sup>28</sup> .  The total amount of pre-financing and interim payment shall not exceed 80% of the maximum grant amount	(a) interim technical report (b) interim financial statement
Payment of the balance  ECDC will establish the amount of this payment on the basis of the calculation of the final grant amount (see section 12.5 above). If the total of earlier payments is higher than the final grant amount, the partner will be required to reimburse the amount paid in excess by the ECDC through a recovery order <sup>29</sup> .	<ul> <li>(a) final technical report;</li> <li>(b) final financial statement;</li> <li>(c) summary financial statement aggregating the financial statements already submitted previously and indicating the receipts</li> <li>(d) a certificate on the financial statements and underlying accounts (i.e. external audit report)</li> </ul>

#### 12.7. Other financial conditions

#### a) Non-cumulative award 30

An action may only receive one grant from the EU budget.

In no circumstances shall the same costs be financed twice by the Union budget. To ensure this, applicants shall indicate in the grant application the sources and amounts of Union funding received or applied for the same action or part of the action or for its (the applicant's) functioning during the same financial year as well as any other funding received or applied for the same action.<sup>31</sup>

#### b) Non-retroactivity<sup>32</sup>

No grant may be awarded retrospectively for actions already completed.

#### c) <u>Implementation</u> contracts/subcontracting<sup>33</sup>

<sup>&</sup>lt;sup>27</sup> Article 109, 110 RAP

<sup>&</sup>lt;sup>28</sup> Article 109, 110 RAP

<sup>&</sup>lt;sup>29</sup> Article 109, 110 RAP

<sup>30</sup> Article 129 FR

<sup>&</sup>lt;sup>31</sup> Article 196.4 RAP

<sup>32</sup> Article 130 FR

<sup>33</sup> Article 137 FR, 209 RAP

Where the implementation of the action requires the award of procurement contracts (implementation contracts), the partner must award the contract to the bid offering best value for money or the lowest price (as appropriate), avoiding conflicts of interests.

Please refer to the Model FPA, Article II.9, Annex III(a).

#### d) Financial support to third parties<sup>34</sup>

The applications may not envisage provision of financial support to third parties.

#### 13. PUBLICITY

#### 13.1. By the Partner

The partner, or the consortium members if consortium, must clearly acknowledge the European Union's contribution in all publications or in conjunction with activities for which the grant is used.

Please refer to the Model FPA, Article II.7, Annex III (a).

#### **13.2.** By ECDC<sup>35</sup>

With the exception of scholarships paid to natural persons and other direct support paid to natural persons in most need, all information relating to grants awarded in the course of a financial year shall be published on an internet site of the European Union institutions no later than the 30 June of the year following the financial year in which the grants were awarded.

ECDC will publish the following information:

- name of the partner;
- address of the partner when the latter is a legal person, region when the partner is a natural person, as defined on NUTS 2 level<sup>36</sup> if he/she is domiciled within EU or equivalent if domiciled outside EU;
- subject of the grant;
- amount awarded.

Upon a reasoned and duly substantiated request by the partner, the publication shall be waived if such disclosure risks threatening the rights and freedoms of individuals concerned as protected by the Charter of Fundamental Rights of the European Union or harm the commercial interests of the beneficiaries.

<sup>&</sup>lt;sup>34</sup> Article 137 FR, 210 RAP

<sup>&</sup>lt;sup>35</sup> Article 35, 128.3 FR, 21, 191 RAP.

<sup>&</sup>lt;sup>36</sup> European Union Official Journal L 39, of 10 February 2007.

#### 14. PROCESSING OF PERSONAL DATA

The reply to any call for proposals involves the recording and processing of personal data (such as name, address and CV). Such data will be processed pursuant to Regulation (EC) No 45/2001 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data. Unless indicated otherwise, the questions and any personal data requested that are required to evaluate the application in accordance with the call for proposal will be processed solely for that purpose by the Centre (ECDC).

Personal data may be registered in the Early Detection and Exclusion System by the Commission, should the partner be in one of the situations mentioned in Article 106(1) and 107 of the Financial Regulation 966/2012<sup>37</sup> (for more information see the Privacy Statement on:

https://ecdc.europa.eu/sites/portal/files/media/en/aboutus/calls/Procurement%20Related%20Documents/ECDC%20-%20Privacy%20Statement.pdf.

#### 15. PROCEDURE FOR THE SUBMISSION OF PROPOSALS

Proposals must be submitted by the deadline set out under section 3.

No modification to the application is allowed once the deadline for submission has elapsed. However, if there is a need to clarify certain aspects or to correct clerical mistakes, ECDC may contact the applicant during the evaluation process<sup>38</sup>.

Applicants will be informed in writing about the results of the selection process.<sup>39</sup>

Application forms are available at <a href="https://ecdc.europa.eu/en/about-us/procurement-and-grants?f[0]=deadline\_date%3A1">https://ecdc.europa.eu/en/about-us/procurement-and-grants?f[0]=deadline\_date%3A1</a>.

Applications must be submitted in the correct form, duly completed and dated. They must be submitted in 5 copies (one original clearly identified as such, plus four copies) and signed by the person authorised to enter into legally binding commitments on behalf of the applicant organisation.

Where applicable, all additional information considered necessary by the applicant can be included on separate sheets.

Applications must be sent to the following address<sup>40</sup>:

European Centre for Disease Control and Prevention (ECDC)

Attn: Procurement Back Office

European Reference Laboratory Network for Tuberculosis (ERLTB-Net) - To Strengthen TB Diagnosis in the European Union and European Economic Area (Grant/2017/OCS/8624)

Granits väg 8 171 65 Solna Sweden

by post, date as postmark;

27

<sup>&</sup>lt;sup>37</sup> http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32012R0966

<sup>38</sup> Article 96 FR

<sup>&</sup>lt;sup>39</sup> Article 133 FR, 205 RAP

<sup>&</sup>lt;sup>40</sup> Article 195.3 RAP

- in person, date as receipt,
- by courier service, date of receipt by the courier service.

Applications sent by fax or e-mail will not be accepted.

#### **Contacts**

ECDC.procurement@ecdc.europa.eu;

With Grant/2017/ OCS/8624 in the subject line.

#### > Annexes:

- Annex I Application form and checklist of documents to be provided
- Annex II Estimated Budget form
- Annex III(a) Model framework partnership agreement
- Annex III(b) Model specific grant agreement